Literature DB >> 33787887

Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update.

Claudia Slimings1, Thomas V Riley2,3.   

Abstract

BACKGROUND: Antibiotic use is the most important modifiable risk factor for healthcare facility-associated Clostridioides difficile infection (HCFA-CDI). Previous systematic reviews cover studies published until 31 December 2012.
OBJECTIVES: To update the evidence for associations between antibiotic classes and HCFA-CDI to 31 December 2020.
METHODS: PubMed, Scopus, Web of Science Core Collection, WorldCat and Proquest Dissertations & Theses were searched for studies published since 1 January 2013. Eligible studies were those conducted among adult hospital inpatients, measured exposure to individual antibiotics or antibiotic classes, included a comparison group and measured the occurrence of HCFA-CDI as an outcome. The Newcastle-Ottawa Scale was used to appraise study quality. To assess the association between each antibiotic class and HCFA-CDI, a pooled random-effects meta-analysis was undertaken. Meta-regression and subgroup analysis was used to investigate study characteristics identified a priori as potential sources of heterogeneity.
RESULTS: Carbapenems and third- and fourth-generation cephalosporin antibiotics remain the most strongly associated with HCFA-CDI, with cases more than twice as likely to have recent exposure to these antibiotics prior to developing HCFA-CDI. Modest associations were observed for fluoroquinolones, clindamycin and β-lactamase inhibitor combination penicillin antibiotics. Individual study effect sizes were variable and heterogeneity was observed for most antibiotic classes.
CONCLUSIONS: This review provides the most up-to-date synthesis of evidence in relation to the risk of HCFA-CDI associated with exposure to specific antibiotic classes. Studies were predominantly conducted in North America or Europe and more studies outside of these settings are needed.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33787887     DOI: 10.1093/jac/dkab091

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children.

Authors:  Shane J Cross; Theodore H Morton; Joshua Wolf
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 3.164

Review 2.  Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis.

Authors:  Alberto Enrico Maraolo; Maria Mazzitelli; Emanuela Zappulo; Riccardo Scotto; Guido Granata; Roberto Andini; Emanuele Durante-Mangoni; Nicola Petrosillo; Ivan Gentile
Journal:  Antibiotics (Basel)       Date:  2022-01-30

Review 3.  Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice.

Authors:  Laura Armengol Álvarez; Greet Van de Sijpe; Stefanie Desmet; Willem-Jan Metsemakers; Isabel Spriet; Karel Allegaert; Jef Rozenski
Journal:  Antibiotics (Basel)       Date:  2022-05-21

Review 4.  It's about the patients: Practical antibiotic stewardship in outpatient settings in the United States.

Authors:  Alpesh N Amin; E Patchen Dellinger; Glenn Harnett; Bryan D Kraft; Kerry L LaPlante; Frank LoVecchio; James A McKinnell; Glenn Tillotson; Salisia Valentine
Journal:  Front Med (Lausanne)       Date:  2022-07-27

Review 5.  Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.

Authors:  Deirdre A Collins; Thomas V Riley
Journal:  Lett Appl Microbiol       Date:  2022-02-11       Impact factor: 2.813

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.